DaVita (NYSE:DVA) Releases FY 2022 Earnings Guidance

DaVita (NYSE:DVAGet Rating) updated its FY 2022 earnings guidance on Monday. The company provided earnings per share guidance of $7.50-$8.50 for the period, compared to the consensus earnings per share estimate of $8.25. The company issued revenue guidance of -.

Several brokerages have issued reports on DVA. Truist Financial cut their price objective on DaVita from $125.00 to $110.00 in a research note on Friday, May 6th. StockNews.com cut DaVita from a strong-buy rating to a buy rating in a research note on Thursday, May 5th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of Hold and an average target price of $130.50.

DVA stock traded down $1.41 during mid-day trading on Monday, reaching $98.64. 6,043 shares of the stock traded hands, compared to its average volume of 677,001. DaVita has a 52-week low of $94.38 and a 52-week high of $136.48. The stock’s fifty day moving average is $112.64 and its 200-day moving average is $110.07. The company has a market cap of $9.33 billion, a P/E ratio of 11.78, a P/E/G ratio of 1.22 and a beta of 1.13. The company has a current ratio of 1.29, a quick ratio of 1.25 and a debt-to-equity ratio of 8.53.

DaVita (NYSE:DVAGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.24). The firm had revenue of $2.82 billion during the quarter, compared to analyst estimates of $2.89 billion. DaVita had a return on equity of 78.24% and a net margin of 7.78%. The company’s revenue for the quarter was down .1% on a year-over-year basis. During the same period in the prior year, the business posted $2.09 EPS. Equities research analysts expect that DaVita will post 7.79 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in DVA. BlackRock Inc. boosted its stake in shares of DaVita by 1.2% during the 4th quarter. BlackRock Inc. now owns 5,654,952 shares of the company’s stock valued at $643,305,000 after buying an additional 67,744 shares during the period. Allianz Asset Management GmbH grew its position in DaVita by 1.2% in the first quarter. Allianz Asset Management GmbH now owns 368,848 shares of the company’s stock worth $41,720,000 after acquiring an additional 4,524 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of DaVita by 266.1% in the first quarter. Hsbc Holdings PLC now owns 239,223 shares of the company’s stock worth $27,193,000 after buying an additional 173,878 shares during the last quarter. Rhumbline Advisers grew its holdings in DaVita by 2.4% in the 1st quarter. Rhumbline Advisers now owns 150,167 shares of the company’s stock valued at $16,985,000 after buying an additional 3,474 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of DaVita by 26.1% in the first quarter. First Trust Advisors LP now owns 129,093 shares of the company’s stock valued at $14,602,000 after buying an additional 26,723 shares during the period. Hedge funds and other institutional investors own 87.47% of the company’s stock.

DaVita Company Profile (Get Rating)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Recommended Stories

Earnings History and Estimates for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.